Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Transcode Therapeutics Inc (NQ: RNAZ ) 0.2351 +0.0024 (+1.03%) Streaming Delayed Price Updated: 2:28 PM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Transcode Therapeutics Inc < Previous 1 2 3 Next > TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA October 16, 2023 Study showed a 70% Inhibition of Recurrent Tumor Growth From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Closing of $8.5 Million Public Offering September 28, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Pricing of $8 Million Public Offering September 25, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise September 26, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END Via FinancialNewsMedia TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138 September 25, 2023 Further Supports TTX-MC138 Application in Brain Cancer From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial August 23, 2023 Designed to demonstrate delivery of TTX-MC138 to metastatic lesions From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update August 14, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138 July 31, 2023 Further Supporting TTX-MC138 Application in Metastatic Cancer From TransCode Therapeutics, Inc. Via GlobeNewswire Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi July 13, 2023 Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to... Via Newsfile TransCode Therapeutics CEO Letter to Shareholders July 05, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer June 22, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Closing of $7 Million Public Offering June 09, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Pricing of $7 Million Public Offering June 06, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma June 06, 2023 Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces 1-for-20 Reverse Stock Split May 22, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial April 27, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio April 26, 2023 Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.” From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas April 14, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics to present at AACR Annual Meeting 2023 April 06, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138 April 05, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock April 04, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock April 03, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports 2022 Results; Provides Business Update March 31, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer February 28, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment February 22, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules February 17, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules February 16, 2023 From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma January 31, 2023 Study provides additional support for further advancement of TTX-RIGA From TransCode Therapeutics, Inc. Via GlobeNewswire TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial December 29, 2022 From TransCode Therapeutics, Inc. Via GlobeNewswire Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028 December 08, 2022 EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence COVID-19 < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.